Literature DB >> 17926975

Thrombocytosis in advanced epithelial ovarian cancer.

Tanomsiri Soonthornthum1, Veera Suraseraneewong, Karun Kengsakol, Kasem Wijaithum, Panon Kasemsan, Sinat Prommatt.   

Abstract

OBJECTIVE: Thrombocytosis (platelet count greater than 400,000/mm3) has been identified as a poor prognostic factor in many cancers. The objectives of the present study were to determine the incidence of thrombocytosis in advanced epithelial ovarian cancer and the cut off point level of platelet count in Thai patients determining thrombocytosis condition and association between survival time in both thrombocytosis condition (platelet count greater than 400,000/mm3 and 305,000/mm3).
DESIGN: Descriptive study. MATERIAL AND
METHOD: One hundred and twenty epithelial ovarian cancer patients were included between January 2004 and December 2005. Their medical records were retrospectively reviewed and data was analyzed using chi2, Fisher's exact test, and Student t- test. The level of platelet counts determining thrombocytosis condition in Thai patients were record and analyzed by ROC curve. Survival was analyzed by the method of Kaplan and Meier.
RESULTS: When using the standard criteria of thrombocytosis (platelet counts greater than 400,000/mm3), the incidence was 35% (42/120 cases). Among advanced-stage patients, such incidence was 56.7% (42/74 cases). The criteria for diagnosis of thrombocytosis in the present study was platelet counts greater than 305,000/ mm3. When using such criteria, the overall incidence of thrombocytosis was 49.1% (59/120 cases) and was 72.97% (54/74 cases) in advanced stage. Patients with preoperative thrombocytosis were found to have higher CA - 125 level, greater prevalence of ascites, and worse prognosis.
CONCLUSION: The incidence of thrombocytosis in Thai patients with advanced epithelial ovarian cancer was 56.7% and 72.9% when using platelet count level greater than 400,000/mm3 and 305,000/mm3 respectively, which was higher than that of the early stage. This implies that thrombocytosis is probably a marker of cancer aggressiveness.

Entities:  

Mesh:

Year:  2007        PMID: 17926975

Source DB:  PubMed          Journal:  J Med Assoc Thai        ISSN: 0125-2208


  6 in total

1.  INSR gene polymorphisms correlate with sensitivity to platinum-based chemotherapy and prognosis in patients with epithelial ovarian cancer.

Authors:  J-L Hu; X-L Hu; Q Han; A-Y Guo; C-J Wang; Y-Y Wen; S-D Cang
Journal:  Gene Ther       Date:  2017-04-24       Impact factor: 5.250

2.  Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer.

Authors:  Supachai Raungkaewmanee; Siriwan Tangjitgamol; Sumonmal Manusirivithaya; Sunamchok Srijaipracharoen; Thaovalai Thavaramara
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

3.  Thrombocytosis is a significant indictor of hypercoagulability, prognosis and recurrence in gastric cancer.

Authors:  Changyuan Hu; Renpin Chen; Wenjing Chen; Wenyang Pang; Xiangyang Xue; Guangbao Zhu; Xian Shen
Journal:  Exp Ther Med       Date:  2014-04-29       Impact factor: 2.447

Review 4.  Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.

Authors:  Edgars Endzeliņš; Vita Melne; Zane Kalniņa; Vilnis Lietuvietis; Una Riekstiņa; Alicia Llorente; Aija Linē
Journal:  Mol Cancer       Date:  2016-05-18       Impact factor: 27.401

5.  Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.

Authors:  Gabriella D Cozzi; Jacob M Samuel; Jason T Fromal; Spencer Keene; Marta A Crispens; Dineo Khabele; Alicia Beeghly-Fadiel
Journal:  BMC Cancer       Date:  2016-08-08       Impact factor: 4.430

Review 6.  Platelets, Thrombocytosis, and Ovarian Cancer Prognosis: Surveying the Landscape of the Literature.

Authors:  Demetra H Hufnagel; Gabriella D Cozzi; Marta A Crispens; Alicia Beeghly-Fadiel
Journal:  Int J Mol Sci       Date:  2020-10-31       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.